Source comparison
How to Use Thymosin Alpha-1 for Infection Defense Protocol: Research Compound Comparison
Before committing to thymosin alpha-1, researchers often evaluate alternative immunomodulatory peptides with overlapping mechanisms. This table compares thymosin alpha-1 against thymulin (another thymic peptide), thymosin beta-4 (which shares naming but differ
This comparison does not assign a generated winner or score.
- Before committing to thymosin alpha-1, researchers often evaluate alternative immunomodulatory peptides with overlapping mechanisms. This table compares thymosin alpha-1 against thymulin (another thymic peptide), thymosin beta-4 (which shares naming but different function), and LL-37 (an antimicrobial peptide with immune effects).
- Thymosin Alpha-1
- TLR activation, T-cell differentiation
- Th1 cytokine upregulation (IL-2, IFN-γ)
- 1.6–3.2mg twice weekly
- 28 days at 2–8°C
- Gold standard for infection defense. Clinical evidence in hepatitis B/C and sepsis models strongest among thymic peptides
- Thymalin
- Thymic epithelial regulation
- Broad thymic hormone restoration
- 5–10mg daily for 5–10 days
- 14 days at 2–8°C
- More generalized immune restoration; lacks thymosin alpha-1's targeted TLR-mediated viral defense
- Thymosin Beta-4
- Actin sequestration, wound healing
- Tissue repair, not direct immune modulation
- 2–5mg twice weekly
- 21 days at 2–8°C
- Primarily regenerative. Minimal direct infection defense application compared to alpha-1
- LL-37 (Cathelicidin)
- Direct antimicrobial activity
- Bacterial membrane disruption
- 2mg daily (experimental)
- 7 days at 2–8°C (highly unstable)
- Potent antibacterial in vitro; limited human data and poor solution stability restrict practical use
- Thymosin alpha-1's advantage over alternatives lies in its dual mechanism: it doesn't just kill pathogens (like LL-37) or generically 'boost immunity' (like thymulin). It specifically enhances the adaptive immune response pathways that recognize and eliminate infected cells, which is why hepatitis and sepsis trials show measurable mortality reduction with thymosin alpha-1 but not with most other immunomodulatory peptides.